Slide 1: Getinge – Passion for Life
Getinge – Passion for Life Investor Relations Deck April 2026
Slide 2: We make life-saving technology accessible for more people
We make life-saving technology accessible for more people Page 2
Slide 3: Key facts
Key facts 35 1904 BSEK 85% Founded in Getinge, Net sales 2025 85% of sales go to hospitals, 15% to Sweden pharma & research Approx. 30,000 Gothenburg Approx.12,000 Customers HQ located in Co-workers in >135 countries Sweden worldwide Page 3
Slide 4: Top 10 markets
Top 10 markets Representing about 75% of total sales in 2025 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% US China Germany France Japan Great Britain Italy Spain Canada Australia Page 4
Slide 5: Making a difference
Making a difference All people and societies need access to best possible care 18 million people die each year from cardiovascular diseases, making it the number 1 cause of death globally.* Hundreds of millions of people are affected by health care acquired infections (HAI) each year.* In the U.S. a
Slide 6: Empowering our customers with knowledge, technology and resources
Empowering our customers with knowledge, technology and resources Intensive Cardiovascular Operating Sterile Life Care Procedures Rooms Reprocessing Science We are working together with our customers within five areas to improve clinical and economic results Page 6
Slide 7: Intensive Care
Intensive Care Aiming to improve clinical outcomes and reduce length of stay Innovative and sustainable life supporting solutions for patients with acute medical conditions, post-operative patients and for neonates. Offering include: • ICU & NICU ventilation • Extracorporeal life support • Advanced
Slide 8: Cardiovascular Procedures
Cardiovascular Procedures Therapies supporting faster recoveries and less risk of complications Cardiovascular therapies and solutions that aim to enable more effective interventions, where patients experience better outcomes and faster recovery, today and in the future. Offering include: • Covered
Slide 9: Operating Rooms
Operating Rooms Bringing the most out of the operating room Therapies and equipment ensuring that surgical procedures go according to plan for everyone involved, and that operating rooms are consistently used to its full capacity. Offering include: • Architectural planning • Digital OR solutions for
Slide 10: Sterile Reprocessing
Sterile Reprocessing Enabling sterilized surgical instruments on time, for each procedure Optimizing sterile reprocessing is about timing and control, to prevent infections and keep surgical procedures on time. Offering include: • Sterilizers • Endoscopy equipment • Washer-disinfectors • Workflow
Slide 11: Life Science
Life Science Preventing contamination in research and production From research laboratories to pharmaceutical production, we support every step of your journey. With focus on contamination prevention and upstream bioprocessing, we provide tailored solutions to scientists and engineers who are dedica
Slide 12: Digital Health Solutions
Digital Health Solutions Page 12
Slide 13: Digital Health Solutions
Digital Health Solutions Simplifying life for hospital staff Contributing to better working conditions while optimizing workflows through advanced technology (e.g., AI, BI, Automation) and connected devices/equipment. INSIGHT Patient Flow Management Tegris OR Integration Torin OR Management T-DOC St
Slide 14: Sustainability
Sustainability GETINGE 3%
Slide 15: Sustainability is an integral part of our strategy
Sustainability is an integral part of Excel in Quality our strategy as we want to shape a and Responsible future where healthcare is better, Business efficient and accessible. ‘Quality and Responsible Business’ together with ‘Engaged Employees’ form the backbone of the sustainability approach. ‘Sust
Slide 16: Committed to net zero emissions by 2050
Committed to net zero emissions by 2050 Science Based Targets initiative (SBTi) approved 2021 2030 2050 >90% reduction of all scope Net zero*** Base year 1 & 2 emissions* 25% reduction scope 3** (Reduction of emissions excluding offsetting) *** Net zero means reducing our (scope 1, 2 & 3) emissions
Slide 17: Where our solutions come to life
Where our solutions come to life Page 17
Slide 18: Production sites around the world
Production sites around the world 23 production sites in 9 countries United States Poland Englewood, Mahwah, Poznan Merrimack, Wayne, Fraser, Smithfield Turkey Antalya Germany Hechingen, Rastatt, United Kingdom Feldkirchen Derby France The Netherlands Ardon, La Ciotat, Delft Tournefeuille, Vendôme,
Slide 19: Our history
Our history GETINGE 3%
Slide 20: This is Getinge
This is Getinge Making life-saving technology accessible for more people 2022–now Acquisitions Founded continue to broaden the 1904 Acquisition of offering Independence Maquet - Building a brings to start cardiovascular provisioning success presence operating Expansion theatres within acute From Ini
Slide 21: Our organization
Our organization GETINGE 3%
Slide 22: Approx. 12,000 co-workers
Approx. 12,000 co-workers of which... • 1,000 work in Research & • 2,800 work in production Development • 4,700 work in supporting functions • 1,500 work with field sales • 1,900 work with field service Page 22
Slide 23: Our organization
Our organization President & CEO Human Quality Compliance, Regulatory & Resources Medical Affairs Sustainability, Finance Legal & Compliance Brand & Communication Global Sales Acute Care Surgical Life (10 sales regions) Therapies Workflows Science Page 23
Slide 24: Getinge Executive Team
Getinge Executive Team Mattias Perjos President & CEO Magnus Lundbäck EVP Human Resources Joanna Engelke EVP Quality Compliance, Regulatory & Medical Affairs Anna Romberg EVP Sustainability, Legal & Compliance Agneta Palmér Chief Financial Officer Alexandra Holland EVP Communications Carsten Blecker
Slide 25: Extract - Latest Capital Market Update
Extract - Latest Capital Market Update May 2024 Page 25
Slide 26: Getinge's expected growth as normalization takes place
Getinge’s expected growth as normalization takes place 2024-2028 Projected organic growth in net sales 2024-2028 • 3-6% Key factors in projection • Negative financial impact from Cardiopulmonary and Cardiac Assist • Normalization in mix towards high margin products in Life Science and Surgical Workf
Slide 27: Acute Care Therapies
Acute Care Therapies Challenges still impacting – expecting continued negative effects Projected organic growth in net sales 2024-2028 • 3-5% Key factors in projection • Product challenges in Cardiac Assist and Cardiopulmonary in US impacting negatively in 2024-2028 (as presented previously) • Conso
Slide 28: Life Science
Life Science Biopharma segment expected to bottom out in 2024-2025 Projected organic growth in net sales 2024-2028 •6-10% Key factors in projection •Low to mid-teen growth in Biopharma •GLP-1 supporting healthy capital goods business •Uncertainty when it comes to China •Continued partnerships with k
Slide 29: Surgical Workflows
Surgical Workflows Main growth opportunities in consumables, new segments and digital solutions Projected organic growth in net sales 2024-2028 •4-6% Key factors in projection •Low single digit growth in core capital equipment and service segments •Double digit growth expected in digital solutions a
Slide 30: Financial target and dividend policy for 2024-2028
Financial target and dividend policy for 2024-2028 >12% 30-50% Adjusted EPS, CAGR Dividend of Net Profit Base year: 2023. Assumptions: average organic net sales growth of 3-6% and adj. EBITA margin in line with the structurally motivated margin of ~16-19% by 2028. Page 30
Slide 31: Updated sustainability targets
Updated sustainability targets Based on a double materiality analysis – relevant priorities integrated in the Corporate Strategy Social • Employee engagement: >70% • Quality regulatory compliance, audit findings per inspection: <1.5 findings Environment • Reduce Scope 1 and 2 emissions by 90% by 203
Slide 32: Productivity improvements ahead
Productivity improvements ahead Continuous improvements within the structure – healthy support to margins Effective processes in purchasing, production, logistics, sales, quality and Portfolio pruning Quality Value Engineering Consolidation of suppliers service Potential structural cost adjustments
Slide 33: Getinge's structurally motivated EBITA margin
Getinge’s structurally motivated EBITA margin 2024-2028 % 19.3% Reduced costs due to lock down ~16-19% Operating leverage Positive mix Acute Care Therapies: Low-Mid 20s Life Science: Mid 10s Surgical Workflows: Low 10s Adjusted EBITA-margin Quality issues (~800 MSEK 2023) 12.5% Negative mix (expecti
Slide 34: Extract – Latest Quarterly Report
Extract – Latest Quarterly Report Q1 2026 Page 34
Slide 35: Organic growth, strong cash flow and regulatory milestone
Organic growth, strong cash flow and regulatory milestone Getinge Q1 2026 Mattias Perjos, CEO Agneta Palmér, CFO
Slide 36: Key pillars for Getinge's profitable growth journey
Key pillars for Getinge’s profitable growth journey Development for strategic KPIs Increase share from recurring revenue Increase sales share from high margin products1 Less field actions per Bn SEK Net sales Capital goods Recurring revenue Rest of Portfolio High margin products -58% 1,9 1,2 1,0 66%
Slide 37: Key takeaways
Key takeaways Q1 2026 • Net sales grew by 0.8% organically and order intake increased by 3.9% organically • Margins in the quarter still heavily impacted by currency and tariffs – yet underlying solid improvement • Strong cashflow and financial position 38,000 53 16 36,000 34,092 52 15 34,000 51 50.
Slide 38: Key activities and events
Key activities and events Q1 2026 Offering and Customers Sustainability and Quality • Situation in the Middle East – First priority is our employees • CE approval for Cardiohelp II, the next generation of the and customers in the region. Limited impact on top line so far. transportable extracorporea
Slide 39: Cardiohelp II - The new flagship in the ECLS market
Cardiohelp II - The new flagship in the ECLS market Excellence. Advanced. Increased mobility Even easier Attachable gas to operate blender Strong clinical Decision support performance functionality Q1 2026 Q2 2026 Q3 2026 CE-mark approval for Limited Full CE-markets Cardiohelp II market release mark
Slide 40: Solid organic growth in Life Science and Surgical Workflows
Solid organic growth in Life Science and Surgical Workflows Order Intake and Net Sales Bridge Q1 2025 – Q1 2026 Order Intake Net Sales Organic Organic change -1.2% +2.9% +13.3% +3.9% change -4.0% +16.0% +4.0% +0.8% -8.0% 44 -10.5% -668 -70 -763 53 -167 SEK M SEK M 8,632 7,939 8,320 7,443 Q1 2025 Acu
Slide 41: Margins impacted by continued headwinds from currency and tariffs
Margins impacted by continued headwinds from currency and tariffs Adjusted Gross Profit and EBITA Bridge Q1 2025 – Q1 2026 Adjusted Gross Profit Adjusted EBITA Adj GM,% Margin development Q1 2026 60.2 37.6 42.7 51.4 +0.3 pp Adj GP (Q1 2025) (60.6) (39.4) (41.2) (52.1) -1.1 pp Adj OPEX +0.1 pp D&A -0
Slide 42: Getinge continues to have a solid financial position
Getinge continues to have a solid financial position Strong FCF in quarter and good safety margin on leverage FCF positively impacted by improved operating profit… … and leverage continues to be well below 2.5x 1.7 1.6 1.4 1.5 1.5 1.2 1.7 1.6 0.8 1.5 1.5 0.8 1.4 0.5 (1.1x excl. pension liabilities)
Slide 43: Tariffs and FX diluting underlying margin by -1.5 pp
Tariffs and FX diluting underlying margin by -1.5 pp Impact on margin from tariffs and FX Impact on adj EBITA in Q1 2026 Illustrative view on adj EBITA margin excl tariffs and FX in -226* Q1 2025 vs Q1 2026 12,6 12,5 MSEK 12,1 11,1 Q1 2025 Q1 2026 Reported adj EBITA margin Excl tariffs Excl FX and t
Slide 44: Steady traction towards the financial target in 2028
Steady traction towards the financial target in 2028 Main profitability drivers Capital Market Update in May 2024 Adj. EBITA Margin bridge 2023-2028 Main drivers for improved profitability 2026-2028 • Key strategic product launches and regulatory approvals in 2026-2027 ~16-19% Growth • US pharma inv
Slide 45: Outlook 2026
Outlook 2026 Net sales for 2026 expected to increase by 3-5% organically* * Adjusted for the phase out of Surgical Perfusion, which is expected to have net sales in 2026 declining from about 250 MSEK to 50 MSEK Getinge │ Presentation │ Q1 Report 2026 April 21, 2026
Slide 46: Getinge – Passion for Life
“= Se A GETINGE PASSION FOR LIFE